核苷(酸)类似物抗病毒治疗乙肝相关性肝癌的临床疗效及对预后的影响  

Clinical Efficacy of Nucleoside Analogue in the Treatment of Hepatitis B Related Hepatocellular Carcinoma and Its Influence on Prognosis

作　　者：刘美三[1] 

机构地区：[1]广州市花都区人民医院,广州510800

出　　处：《数理医药学杂志》2018年第2期256-257,共2页Journal of Mathematical Medicine

摘　　要：目的:探讨核苷(酸)类似物抗病毒治疗乙肝相关性肝癌的临床疗效。方法:选取某院2012年8月~2015年7月收治的77例乙肝相关性肝癌行介入术或根治术患者为研究对象,根据术后是否接受核苷(酸)类似物抗病毒治疗分为观察组41例,对照组36例,观察手术前后血清HBV DNA载量、中位生存时间及生存率。结果:观察组术后不同时间的HBV DNA载量明显低于对照组(P<0.05);观察组中位生存时间明显较对照组长(P<0.05);观察组术后6个月、1年、2年的生存率分别为85.37%、48.78%、29.27%,均高于对照组(P<0.05)。结论:乙肝相关性肝癌介入术或根治术后给予规范化核苷(酸)类似物抗病毒治疗能改善患者预后,延长生存期,具有一定推广价值。Objective:To investigate the clinical efficacy of nucleoside analogues in the treatment of hepatitis B associated liver cancer.Methods:77 cases of patients with hepatitis B associated liver cancer treated in a hospital from August 2012 to July 2015 were selected as the research object and divided into observation group(41 cases)and control group(36 cases)according to whether or not to receive nucleoside(acid)analogue antiviral therapy after operation.The serum HBV DNA load,median survival time and survival rate were observed before and after operation.Results:The HBV DNA load at different time after the operation in the observation group was significantly lower than that in the control group(P<0.05).The median survival time of the observation group was significantly longer than that of the control group(P<0.05);the median survival time of observation group was significantly better than the control group(P<0.05);The survival rate in the observation group after 6 months,1 years and 2 years was 85.37 %,48.78 % and 29.27 %,respectively,which was higher than those in the control group(P<0.05).Conclusion:The normalization of nucleoside(acid)analogue antiviral therapy in the treatment of hepatitis B related liver cancer after interventional or radical operation can improve the prognosis of patients,prolong the survival time,and has certain popularization value.

关 键 词：核苷(酸)类似物 乙肝相关性肝癌 抗病毒治疗 

分 类 号：R735.7[医药卫生—肿瘤]